Second Line Capital’s GSK GSK Stock Holding History

Second Line Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,955	Closed	-$245K	–	138
2024 Q3	$245K	Buy	+5,955	New	+$244K	0.07%	108

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Second Line Capital's GSK Position: Q4 2024 in Review

Second Line Capital sold out of GSK (GSK) in Q4 2024, closing a stake of 5,955 shares — an estimated $245K sold.

Second Line Capital first reported a position in GSK in Q3 2024 and held it in 1 quarter. The position peaked at $245K in Q3 2024. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

Second Line Capital reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
Second Line Capital sold 5,955 GSK shares in Q4 2024, an estimated $245K.
Second Line Capital first reported a position in GSK in Q3 2024 and held it in 1 quarter.
Second Line Capital's GSK position peaked at $245K in Q3 2024.
848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on Second Line Capital's 13F filing for Q4 2024, filed 14 Feb 2025.